Corel Medical Series: Cancer/Corel Medical Series: Cancer.iso/mac/Program/Indexdat/indexc.P

Text File | 1997-01-27 | 5KB | 2 lines

Paget's disease,4,Pain,11,Pain Control Ladder,p19.8,PALA,4,Palladium,c35.22,Palliative care,4,Palliative care nurse,p15.11,Pancreas diagram,c13.8,Pancreas islet cell carcinoma,c08.2,Pancreatectomy,c15.10,Pancreatic cancer,13,Pancreaticoduodenal resection,c31.10,Pancreatitis,c31.7,Pap smear,p02.5;p34.18,Papillary carcinoma,2,Papilloma bladder,c04.3;c04.17,Papillomatosis,c06.5,Paranasal sinus tumor,c14a.1;c14a.7;c14b.8,Parathyroid cancer,12,Parathyroid gland diagram,c42.6,Paregoric,p18.20,Parenteral nutrition (TPN),p18.13,Passive immunotherapy,p08.6,Pathologist,p03.3,Patient controlled analgesia,p05.15,Patients Active,p30.1;p30.9,Patients Passive,p30.1,The Pediatric Oncology Group,c10a.12;c10a.15;c10b.1;c10b.8,Pediatrician,p03.3,Pelvic exenteration,c09.24,Penectomy,c33.9,Penile cancer,10,Pentamidine,c16.16,Peptamen,p18.12,Percocet,p19.8;p19.13,Percodan,0,Percutaneous gastrostomy (PEG),p18.12,Periactin,c08.9,Peridural anesthesia,p05.16,Peritoneum,c07.3,Pethidine,p19.8;p19.13,Peutz-Jeghers syndrome,c38.4,Pharmacist,p03.6,Phenacetin,c04.4,Phenazopyridine hydrochloride,p06.20,Phenobarbital,c05.27,Phenoxybenzamine,c15.15,Pheochromocytoma,c01.1;c01.4;c01.6;c01.7;c01.8;c01.10;c01.14;c01.17,Pheoxybenzamine,c01.15,Philadelphia chromosome,p36.8,Phosphasoda,p17.24,Phosphorus radioactive,p06.11,Photocoagulahon therapy,c10c.4,Photodynamic therapy,p09.4;c37.19,Physical examination,2,Physical therapist,p03.6,Physical therapy,p24.5,Physician Data Query (PDQ) system,9,Pineal tumor child,c10b.2;c10b.7;c10b.19,Pinealblastoma,c05.11,Pituitary adenoma,c05.20,Pituitary cancer,8,Pituitary gland,c34.1,Plasma cell leukemia,c28.2,Plasmacytoma,c28.3,Platinum,2,PNET (Primitive neuroectodermal tumor),c10a.2;c10b.6;c10b.7;c10b.10;c10d.1;c10d.10,Pneumonia,p12.12;p20.5,Podophyllin,c33.12,Polymerase chain reaction,c07.10,Polymorphonuclear leukocyte (PMN),p08.4,Ports,p05.8;p05.7;p07.10,Positron emission tomography (PET scan),p33.10,Power of Attorney,p32.4;p32.5;p32.6,Pre-cancerous conditions,p05.3,Pre-deposit donation,p14.10,Precision Low Residue,p17.27,Preclinical drug testing,p35.3,Prednisone,8,Pregnancy,3,Preleukemia,c18.12,Premarin,p23.21,Premature ovarian failure,p23.20,Preserved foods,p34.7,Prevention,6,Procarbazine,5,Prochlorperazine,chr.p17.14;p18.20;c18.17,Proctologist,p03.4,Progesterone,p07.6;p23.19,Progression after chemotherapy,p07.5,Prolactin-producing tumor,c34.6,Prolymphocytic leukemia,c18.28,Promyelocytic leukemia,p35.15,Propoxyphene,p19.8,Prostate cancer,15,Prostate specific antigen (PSA),p34.18,Prostatectomy,c35.12;c35.21;c35.32,Prostatic hyperplasia,c35.1,Prostatic intraepithelial neoplasia (PIN),c35.2,Prosthesis esophageal,p09.9,Proto-oncogenes,p36.3,Provera,p23.21,Psychedelic drugs,p23.8,Psychiatric nurse,p03.6,Psychiatrist,p03.6,Psychologist,p03.6,Psychosocial care,p27.7,Psychotherapist,p03.6,Psyllium,p17.24,Pulmonary embolism post-operative,p05.18,Pumps,p05.2;p07.9;p07.11;p20.2,Pure endometrial stromal sarcomas,c45.2,Pure red cell aplasia,c41.2,
anus,c02.1,bone,c36.4,breast,c06.2;c06.10,vulva,c47.2;c47.18,after hormone therapy,c06.50,after hyperthermia,p10.5,after surgery,p05.17,causes,p19.3,controlling,p19.7;p25.5;p26.12;p27.5,during intercourse,p23.3;p23.9,fear of,p19.1,from multiple myeloma,c28.17,sign of infection,p20.5,types,p19.3,when urinating,p06.19;p20.5,for colorectal cancer,c11b.9;c11b.13;c11b.20;c11c.9;c11c.11;c11c.15,for pancreatic cancer,c31.11;c31.19,for stomach cancer,c39.16,investigational drug,p35.10,defined,p27.1,goals,p27.5,range of services,p27.2,roles,p27.4,causes,c31.2,diagnosis,c31.6,investigational drugs,p35.9,questions to ask,c31.20,recurrence,c31.19,risk factors,c31.3,screening,c31.4,spread,c31.2,staging,c31.9,symptoms,c31.5,treatment,c31.10,types,c31.1,unknown primary site,c07.1;c07.5,endometrium,c44.2,thyroid,c42.2;c42.3;c42.17,causes,c32.2,diagnosis,c32.6,follow-up,c32.12,questions to ask,c32.14,recurrence,c32.13,risk factors,c32.3,screening,c32.4,spread,c32.2,staging,c32.8,symptoms,c32.5,treatment,c32.9,types,c32.2,causes,c33.2,diagnosis,c33.6,questions to ask,c33.13,risk factors,c33.3,screening,c33.4,and sexuality,p23.7,spread,c33.1,symptoms,c33.5,treatment,c33.7,types,c33.1,breast,c06.8,importance,p02.4;p20.6;p34.17,access,p37.14;p37.16,Canadian participants,p37.15,clinical trials,p37.9,currency,p07.17;p37.5,directory,p37.13,format,p37.4,information available,p37.3,organization,p37.2,protocol file,p37.7,causes,c34.2,diagnosis,c34.4,follow-up,c34.8,questions to ask,c34.9,spread,c34.2,symptoms,c34.3,treatment,c34.5,types,c34.1,for lung cancer,c20.10,for osteogenic sarcoma,c10d.8,for brain tumor,c10b.15,for breast cancer,c06.41,for Hodgkin's disease,c23.15,for leukemia,c18.19,for lymphoma,c22.8;c24.16,for multiple myeloma,c28.12;c28.20,for thymus cancer,c41.9,to restore appetite,p17.20,breast cancer,c06.5,ovarian cancer,c29.5,trophoblastic disease,c43.1;c43.5,advances in,p33.9,defined,p34.2,guidelines,p34.11,objectives (table),chr.p34.2,skin cancer,c37.7,surgical,p05.3,for brain cancer,c05.18,for gastrointestinal tract cancer,c08.14,for Hodgkin's disease,c23.16;c23.16,for lymphoma,c24.16;c24.20,side effects,chr.p17.13,causes,c35.3,diagnosis,c35.9,diagrams,c35.3;c35.20,follow-up,c35.34,questions to ask,c35.37,recurrent,c35.36,risk factors,c35.4,screening,c35.6,and sexuality,p23.8,spread,c35.2,staging,c35.11,symptoms,c35.8,treatment,c35.12,types,c35.2,unknown primary site,c07.1;c07.6;p07.14,